Latest stories on MBRX
Moleculin spotlights completed Part A enrollment in MIRACLE trial, with full 90-patient readout targeted for Q1 2027
October 21, 2026
MarketChameleon58 · neutralproduct/pr
MBRX Jumps After CEO Corner Highlights MIRACLE Trial Enrollment Completion and a Q1 2027 Data Readout
October 20, 2026
MarketChameleon63 · neutralproduct/pr
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
StockTitan58 · neutralproduct/pr
Moleculin Biotech Executes 1-for-20 Reverse Stock Split
TipRanks32 · bearishgeneral
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Biotech trading halted, news pending
The Fly50 · neutralgeneral
Moleculin Biotech Updates Investors With New Presentation
TipRanks52 · neutralproduct/pr
Moleculin announces 1-for-20 reverse stock split, shares slide
Seeking Alpha31 · bearishgeneral
Moleculin Biotech announces 1-for-20 reverse stock split
The Fly31 · bearishgeneral
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Announces Reverse Stock Split
GlobeNewswire31 · bearishgeneral
Moleculin Announces Reverse Stock Split
Business Insider31 · bearishgeneral
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Business Insider56 · neutralproduct/pr
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
GlobeNewswire53 · neutralproduct/pr
Moleculin Biotech Updates Investors With New Presentation
TipRanks55 · neutralgeneral
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial
The Fly59 · neutralproduct/pr
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Business Insider63 · neutralproduct/pr
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
GlobeNewswire63 · neutralproduct/pr
Moleculin Highlights Annamycin Cardiac Safety in New Analysis
TipRanks56 · neutralproduct/pr
Moleculin Biotech announces publication of analysis of Annamycin in Frontiers
The Fly56 · neutralproduct/pr
Moleculin Biotech, Inc. (MBRX) files 8-K
SEC 8-K50 · neutralgeneral
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
StockTitan63 · neutralproduct/pr